Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK +2.17%100 Return-on-Tangible-Equity is 11.83% as of Jun. 2026, which is 13% below its 10-year median of 13.55. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD27,094.78 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 895 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 68.6% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alkaloid AD Skopje's annualized net income for the quarter that ended in Jun. 2026 was MKD1,500 Mil. Alkaloid AD Skopje's average shareholder tangible equity for the quarter that ended in Jun. 2026 was MKD12,673 Mil. Therefore, Alkaloid AD Skopje's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 11.83%.
The historical rank and industry rank for Alkaloid AD Skopje's Return-on-Tangible-Equity or its related term are showing as below:
XMAE:ALK'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.51 Med: 13.55 Max: 14.47
Current: 14.47
During the past 13 years, Alkaloid AD Skopje's highest Return-on-Tangible-Equity was 14.47%. The lowest was 10.51%. And the median was 13.55%.
XMAE:ALK's Return-on-Tangible-Equity is ranked better than 68.6% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.85
vs XMAE:ALK: 14.47
Alkaloid AD Skopje (XMAE:ALK) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Alkaloid AD Skopje Return-on-Tangible-Equity Related Terms
Alkaloid AD Skopje Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkaloid AD Skopje Return-on-Tangible-Equity Chart
XMAE:ALK vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.83% mean?
Alkaloid AD Skopje (XMAE:ALK) has a Return-on-Tangible-Equity of 11.83% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alkaloid AD Skopje and its competitors. This is 13% below median its historical median of 13.55. Over the past decade, Alkaloid AD Skopje's Return-on-Tangible-Equity has ranged from 10.51 to 14.47. According to the industry distribution chart, Alkaloid AD Skopje ranks #281 out of 895 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Alkaloid AD Skopje's Return-on-Tangible-Equity too high?
Alkaloid AD Skopje's current Return-on-Tangible-Equity of 11.83% is 13% below median its 10-year median of 13.55. Over the past 10 years, this metric has ranged from a low of 10.51 to a high of 14.47. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.85. Alkaloid AD Skopje's value of 11.83% is 50.7% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #281 out of 895 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #281 out of 895 companies for Return-on-Tangible-Equity. This puts Alkaloid AD Skopje in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.85. Alkaloid AD Skopje's value of 11.83% is 50.7% above this benchmark. Historically, Alkaloid AD Skopje's own Return-on-Tangible-Equity has ranged from 10.51 to 14.47 over the past decade. While the company's 10-year median is 13.55 vs. the industry median of 7.85, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.85, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current Return-on-Tangible-Equity of 11.83% is 50.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current Return-on-Tangible-Equity is 11.83%, which is 13% below median its own 10-year median of 13.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,094.78, compared to a current price of MKD23,500.00 — trading 13.3% below its estimated fair value. The current Return-on-Tangible-Equity is 11.83%, which is 13% below median its 10-year median of 13.55 and 50.7% above the Drug Manufacturers industry median of 7.85. Alkaloid AD Skopje's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current Return-on-Tangible-Equity is 11.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD23,500.00 is trading 13.3% below its estimated GF Value™ of MKD27,094.78.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
Return-on-Tangible-Equity: 11.83% (13% below median its 10-year median of 13.55)
GF Value™: MKD27,094.78 vs. price of MKD23,500.00 (13.3% below fair value)
Industry Position: 50.7% above the Drug Manufacturers median (#281 of 895)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
